107 results match your criteria: "Oklahoma University Health Science Center[Affiliation]"
J Pediatr Gastroenterol Nutr
August 2001
Oklahoma University Health Science Center, Tulsa, Oklahoma 74129, USA.
Arch Otolaryngol Head Neck Surg
July 2001
Department of Otorhinolaryngology, Oklahoma University Health Science Center, PO Box 26901, WP 1360, Oklahoma City, OK 73190-0001, USA.
Pediatr Infect Dis J
March 2001
Jimmy Everest Cancer Center, Children's Hospital of Oklahoma, Oklahoma University Health Science Center, Oklahoma City 73104, USA.
Background: In view of the recent trend toward monotherapy in the treatment of bacterial infection, we evaluate the clinical efficacy and safety of cefepime vs. ceftazidime for the empiric treatment of febrile episodes in neutropenic pediatric cancer patients.
Methods: In a single site, open label study, 104 neutropenic pediatric cancer patients [96% with absolute neutrophil count (ANC) of <500 neutrophils/mm3] with a median age of 6 years were randomized (1:1) to receive either intravenous cefepime or ceftazidime (50 mg/kg/dose every 8 h; < or = 6 g/day) for empiric treatment of fever (temperature >38.
J Am Acad Dermatol
January 2001
Oklahoma University Health Science Center, Oklahoma City, USA.
Background: Atopic dermatitis can have detrimental effects on health-related quality of life (QOL).
Objective: Our purpose was to examine the QOL impact of tacrolimus ointment in patients with atopic dermatitis.
Methods: The Dermatology Life Quality Index (DLQI), Children's DLQI (CDLQI), and Toddler QOL Survey were used to assess QOL in adults (16 years or older), children (5-15 years), and toddlers (2-4 years) enrolled in 12-week, randomized, double-blind studies comparing two concentrations of tacrolimus ointment (0.
Am J Med
March 1990
Department of Medicine, Oklahoma University Health Science Center, Oklahoma City.
Purpose: Anti-PL-12 antibody is directed at the enzyme alanyl-tRNA synthetase (ARS). Studies have clearly associated anti-Jo-1, also directed at an aminoacyl-tRNA synthetase (histidyl-tRNA synthetase), with a subgroup of myositis marked by a high frequency of interstitial lung disease (ILD) and arthritis. A similar syndrome has been reported in patients with antibodies to PL-12, but few patients have been studied.
View Article and Find Full Text PDFGynecol Oncol
October 1988
Department of Obstetrics and Gynecology, Oklahoma University Health Science Center, Oklahoma City 73190.
In view of the rarity of germ cell tumors of the ovary, it is not surprising that little information exists about the indications for and significance of findings at second-look laparotomy in patients with these tumors. For this reason, we have reviewed 16 patients who received primary chemotherapy for malignant germ cell tumors of the ovary at Memorial Sloan-Kettering Cancer Center (MSKCC) between 1976 and 1983. Eleven of them underwent a second-look laparotomy after completion of their therapy.
View Article and Find Full Text PDFArthritis Rheum
April 1988
Department of Medicine, Oklahoma University Health Science Center, Oklahoma City.
The prevalence and clinical correlations of anti-threonyl-transfer RNA synthetase (anti-PL-7), as well as the relationship of anti-PL-7 to anti-histidyl-transfer RNA synthetase (anti-Jo-1) were studied in 109 sera from patients with myositis. Inhibition of threonine aminoacylation was used to screen for anti-PL-7. Sera from 3 patients, 2 with polymyositis and 1 with polymyositis-overlap syndrome, and a fourth serum from a patient with dermatomyositis, which was previously found to contain anti-PL-7, inhibited greater than 90% of activity (3.
View Article and Find Full Text PDF